Rabbit Polyclonal ERK2 antibody. Suitable for WB and reacts with Mouse, Human samples. Cited in 55 publications. Immunogen corresponding to Synthetic Peptide within Human MAPK3.
View Alternative Names
ERK2, PRKM1, PRKM2, MAPK1, Mitogen-activated protein kinase 1, MAP kinase 1, MAPK 1, ERT1, Extracellular signal-regulated kinase 2, MAP kinase isoform p42, Mitogen-activated protein kinase 2, ERK-2, p42-MAPK, MAP kinase 2, MAPK 2
- WB
Supplier Data
Western blot - Anti-ERK1 + ERK2 antibody (AB196883)
All lanes:
Western blot - Anti-ERK1 + ERK2 antibody (ab196883) at 1/500 dilution
Lane 1:
NIH/3T3 (Mouse embryo fibroblast cell line) cell extract
Lane 2:
NIH/3T3 (Mouse embryo fibroblast cell line) cell extract with synthesized peptide
Predicted band size: 41 kDa,46 kDa
Observed band size: 46 kDa
false
- WB
Supplier Data
Western blot - Anti-ERK1 + ERK2 antibody (AB196883)
All lanes:
Western blot - Anti-ERK1 + ERK2 antibody (ab196883) at 1/500 dilution
All lanes:
K562 (Human chronic myelogenous leukemia cell line from bone marrow) cell extract
Predicted band size: 41 kDa
false
- WB
CiteAb
Western blot - Anti-ERK1 + ERK2 antibody (AB196883)
ERK1 + ERK2 western blot using anti-ERK1 + ERK2 antibody ab196883. Publication image and figure legend from Liang, R. N., Li, P. S., et al., 2017, Evid Based Complement Alternat Med, PubMed 28656053.
ab196883 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab196883 please see the product overview.
The suppressive effect of PCJNF-containing serum was mediated by JNK signaling pathway in EESCs. (a) EESCs were treated with 20% PCJNF-containing serum and different controls for 0, 24, 48, 72, and 96 h, respectively. The cell viability was assessed by CCK8 assay. Compared with different control groups (CONT, DMSO, and NS), 20% PCJNF-containing serum had significant suppressed effect on cell viability after 24 h, while the JNK inhibitor SP600125 attenuated this effect only after 48 h. The experiment was performed in triplicate. (b) Meanwhile, JNK inhibitor SP600125 deactivates the JNK signaling pathway in EESCs, when compared with different controls (CONT, DMSO, and NS). While there was no significant difference of cell proliferation in EESCs between the "NS" and "NS + SP600125" group (P > 0.05). (c) The total and phosphorylated ERK and p38 of EESCs did not change markedly, when compared with different controls. The experiment was performed in triplicate. NS : rat serum from saline treatment; PCJNF : rat serum with PCJNF treatment.
false
Reactivity data
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
ERK1 and ERK2 play key roles in cell proliferation differentiation and survival. They form part of a cascade that includes upstream activators such as MEK1/2 and downstream targets including transcription factors. As components of the MAPK signaling complex ERK1/2 regulate gene expression through phosphorylation events impacting cellular responses to various stimuli. Their activation often hinges on growth factors cytokines and stress signals facilitating cellular adaptation to environmental changes.
Pathways
Regarding pathways ERK1/2 sit within the MAPK/ERK pathway and are significant in the Ras/Raf/MEK/ERK cascade one of the foremost signaling mechanisms in cells. They interact with several proteins including Ras and Raf which modulate their activation. This pathway is important for transmitting signals from the cell surface to the DNA in the cell nucleus impacting gene regulation and cell fate decisions. ERK1/2 proteins therefore serve as critical nodes linking extracellular signals to cellular responses ensuring balanced cell function.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Additional targets
Publications (55)
Recent publications for all applications. Explore the full list and refine your search
Scientific reports 15:29741 PubMed40804251
2025
Applications
Unspecified application
Species
Unspecified reactive species
Heliyon 9:e17120 PubMed37360090
2023
Applications
Unspecified application
Species
Unspecified reactive species
Environmental toxicology 38:2002-2010 PubMed37219039
2023
Applications
Unspecified application
Species
Unspecified reactive species
Cell cycle (Georgetown, Tex.) 22:718-731 PubMed36404682
2022
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in bioscience (Landmark edition) 27:62 PubMed35227005
2022
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in oncology 11:657008 PubMed34336654
2021
Applications
Unspecified application
Species
Unspecified reactive species
NPJ Regenerative medicine 6:28 PubMed34039998
2021
Applications
Unspecified application
Species
Unspecified reactive species
Pediatric blood & cancer 68:e29086 PubMed33913609
2021
Applications
Unspecified application
Species
Unspecified reactive species
Oncology reports 45: PubMed33786627
2021
Applications
Unspecified application
Species
Unspecified reactive species
Journal of molecular endocrinology : PubMed32698141
2020
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com